{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 74/80', 'APPENDICES', 'APPENDIX 1:', 'KNOWN CYP2C8 SUBSTRATES', 'Excluded medication:', 'Amiodarone', 'Buprenorphine', 'Amiodaquine; Chloroquine', 'Repaglinide', 'Rosiglitazone, pioglitazone', 'Verapamil', 'Zopiclone', 'This list is intended as a guidance for the investigator.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 75/80', 'APPENDIX 2: KNOWN STRONG CYP3A4 INDUCERS AND', 'POTENT P-GP INDUCERS', 'Excluded medication:', 'Barbiturates', 'Carbamazepine', 'Glucocorticoids: steady dose of prednisone or equivalent >10 mg/day', 'Modafinil', 'Oxcarbazepine', 'Phenobarbital', 'Phenytoin', 'Pioglitazone', 'Rifabutin', 'Rifampin', 'Bosentan', \"St. John's Wort\", 'This list is intended as a guidance for the investigator.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 76/80', 'APPENDIX 3:', 'KNOWN STRONG CYP3A4 INHIBITORS', 'Excluded medication:', 'Clarithromycin', 'Itraconazole', 'Ketoconazole', 'Nefazodone', 'Suboxone\u00ae', 'Telithromycin', 'This list is intended as a guidance for the investigator.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}